Semax, in brief. Semax is a short chain of seven amino acids built from a piece of ACTH, the pituitary hormone that normally tells the adrenal glands to release cortisol. It keeps only the four-residue stretch ACTH(4-7), chosen for its activity in the brain rather than its hormonal role, plus a Pro-Gly-Pro tail to slow its breakdown. In rat brain it raises the growth factor BDNF and activates its receptor, trkB, in the hippocampus, a region central to learning and memory [1]. In rats given an experimental cortical stroke, a week of treatment left the damaged area about 20% smaller and the animals kept a learned avoidance task that untreated rats lost [2,8]. In stroke models it also shifts hundreds of genes tied to inflammation, immunity and nerve signalling [3,5,7]. Semax is a registered drug in Russia but is not approved by the FDA [8]. NextGenPeps supplies Semax as a 10 mg lyophilized research material for laboratory use only.
What does Semax do?
In rat studies it does three main things: it switches on a brain growth-factor system, it limits damage after an experimental stroke, and it reshapes the genes the brain turns on after that injury. All of the work below comes from animal and cell studies, most of it from rats.
Growth-factor signalling. A single application raised BDNF protein 1.4-fold and trkB receptor activation 1.6-fold in the rat hippocampus [1].
Stroke damage. In a photothrombotic cortical stroke model, treated rats had infarcts about 20% smaller than vehicle-treated rats and did not show the memory deficit seen in controls [2,8].
Gene programs after ischemia. In middle cerebral artery occlusion models it damped inflammatory genes and lifted genes related to neurotransmission and immune signalling [3,5,7].
NextGenPeps supplies Semax for in vitro research and approved animal studies only. It is not sold as a drug, supplement or nootropic product.
How does Semax work?
The short answer is that its receptor is not settled, but its downstream effects on BDNF, serotonin turnover and gene expression are well documented in rodents.
Semax is a fragment of ACTH, a melanocortin peptide, but it was designed around the fragment's brain activity rather than its role in the adrenal hormone response. The best characterised readout is the BDNF system. In the rat hippocampus, one application raised BDNF protein 1.4-fold, trkB tyrosine phosphorylation 1.6-fold, and the mRNA for BDNF exon III and for trkB 3-fold and 2-fold [1]. In rodent striatum it raised the serotonin metabolite 5-HIAA by 25% in tissue at 2 hours and to 180% of baseline in extracellular fluid over 1 to 4 hours, without changing dopamine on its own; given before d-amphetamine, it strengthened the amphetamine-induced rise in dopamine and in locomotor activity [4].
After experimental ischemia, Semax works largely through gene expression. In a 90-minute transient occlusion model, RNA sequencing found 394 genes changed more than 1.5-fold at 24 hours in Semax-treated versus saline-treated rats, with inflammatory genes suppressed and neurotransmission genes activated [7]. At the protein level, it cut stress-kinase (pJNK) activation by more than 1.5-fold, raised the pro-survival factor pCREB by more than 1.5-fold in the subcortex, and lowered MMP-9 and c-Fos in the cortex [6]. In a permanent occlusion model the most affected process was the immune response [5].

Figure 1. How Semax is built and what it changes. The ACTH(4-7) head and Pro-Gly-Pro tail, and the main readouts reported in rat hippocampus, striatum and ischemic cortex [1,3,4,5,7]. A simplification; the receptor that starts these effects has not been identified.
What did Semax do in animal studies?
Treated rats had smaller strokes and kept a learned task that untreated rats lost.
In the clearest outcome study, rats received a focal photothrombotic stroke in the prefrontal cortex and were then treated intranasally once a day for a week. The infarcted area was about 20% smaller in Semax-treated rats than in vehicle-treated rats, and while vehicle-treated rats showed a memory retention deficit in a passive avoidance task, Semax-treated rats did not [2,8]. Passive avoidance measures whether an animal remembers to stay out of a compartment where it previously had an unpleasant experience, so it is a simple test of learning and memory.
At the molecular level, the hippocampal BDNF system responded within hours of a single dose (Figure 2) [1], and after artery occlusion, Semax shifted markers of cell stress and survival toward the uninjured state [6,7]. Gene-level studies of the stroke models did not report survival or neurological scores, so the functional evidence rests mainly on the infarct and memory results.

Figure 2. What Semax did in rats. Infarct area after a week of treatment, as reported for the Romanova study in the FDA briefing [2,8], and maximal BDNF and trkB changes in the hippocampus after one application [1]. Values come from separate rat studies and are not directly comparable.
Semax vs Selank
Both are seven-residue peptides with the same Pro-Gly-Pro tail, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, but they start from different natural peptides and are studied for different things [10].
Parent peptide. Semax: ACTH(4-7), a melanocortin fragment. Selank: tuftsin (Thr-Lys-Pro-Arg), an immune-system peptide [10].
Sequence. Semax: Met-Glu-His-Phe-Pro-Gly-Pro. Selank: Thr-Lys-Pro-Arg-Pro-Gly-Pro [10].
Molecular weight. Semax: 813.93 g/mol (C37H51N9O10S). Selank: 751.9 g/mol (C33H57N11O9).
Main research focus. Semax: BDNF signalling, stroke models and memory tasks [1,2]. Selank: anxiety-like behaviour and GABAergic signalling; in rat frontal cortex it changed 45 of 84 neurotransmission genes at 1 hour [10].
No published study has compared the two peptides head to head in the same model.
What is Semax made of?
Semax is a linear heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The first four residues are positions 4 to 7 of ACTH; the last three are the tripeptide Pro-Gly-Pro, added to make the peptide more resistant to breakdown. Its molecular formula is C37H51N9O10S and its molecular weight is 813.93 g/mol for the free base. The acetate salt is C39H55N9O12S, 874.0 g/mol [8].
The literature calls it both an ACTH(4-10) analogue and ACTH(4-7)PGP. Both names describe the same molecule: the Pro-Gly-Pro tail replaces the native ACTH residues 8 to 10. The Pro-Gly-Pro tripeptide on its own has been tested as a comparison arm in the stroke studies and produced a different pattern of gene changes from Semax [5].
Semax at a glance
Compound: Semax, ACTH(4-7)-Pro-Gly-Pro
Class: Synthetic heptapeptide; melanocortin (ACTH) fragment analogue
Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Molecular formula: C37H51N9O10S (free base)
Molecular weight: 813.93 g/mol
Strength: 10 mg per vial
Identity and purity: 98.85% purity with identity by UHPLC-MS on the current lot (independent lab, June 19, 2026); certificate published in the COA library
Endotoxin: Under 1 EU per vial on the current lot
Appearance: Lyophilized powder, sealed vial
Reconstitution: Sterile or bacteriostatic water
Half-life: Not established. Semax is quickly hydrolyzed in rat blood and brain tissue, and no clinical pharmacokinetic studies were identified by the FDA [8]
Regulatory status: Registered drug in Russia (0.1% and 1% nasal drops); not FDA approved [8]
Is Semax legal or FDA approved?
Semax is not an FDA-approved drug. It is registered in Russia, where it is available as 0.1% and 1% nasal drops [8].
At its July 23 and 24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee reviewed Semax for the list of bulk substances that may be used in pharmacy compounding. The FDA's own briefing concluded that the evaluation criteria weighed against listing it, citing thin clinical data and gaps in toxicology [8]. The committee nevertheless voted 8 to 5 in favour [9]. The vote is not binding, and the FDA must still complete rulemaking before anything changes. None of this affects its status as a research material.
What is Semax used to study?
Researchers use Semax mainly as a tool to drive the BDNF system and to study protection after brain ischemia.
Ischemic stroke models. Infarct size, memory after cortical stroke, and protein markers of cell stress and survival after artery occlusion [2,6].
Neurotrophin signalling. BDNF and trkB expression and activation in the hippocampus [1].
Transcriptomics of brain injury. Genome-wide changes in immune, vascular and neurotransmission genes after occlusion [3,5,7].
Monoamine systems. Serotonin turnover and amphetamine-induced dopamine release in the striatum [4].
Buying Semax for research: what each vial includes
Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library. The current lot was analysed on June 19, 2026 by UHPLC-MS, with 98.85% purity, and endotoxin came in under 1 EU per vial.
Verified identity, purity and endotoxin. 98.85% purity and under 1 EU per vial endotoxin on the current lot; the certificate is published in the COA library.
US-based fulfilment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.
Research use only. Semax is sold strictly for in vitro and approved animal research. It is not for human or veterinary use and is not sold as a drug, supplement or nootropic.
Semax handling, storage and analytical notes
Format. Supplied as 10 mg lyophilized powder in a sealed vial and reconstituted with sterile or bacteriostatic water. No dosing instructions are supplied, and none should be taken from the studies above.
Storage. Keep the sealed vial at 2 to 8 °C, or -20 °C for longer holding, protected from light. After reconstitution, hold the solution at 2 to 8 °C and avoid repeated freeze-thaw cycles.
Stability in biological samples. Semax is broken down quickly by peptidases in rat blood and brain tissue [8]. Studies measuring it in tissue should process samples promptly and state how breakdown was controlled.
Free base and salt. Semax is handled both as the free base (813.93 g/mol) and as the acetate salt (874.0 g/mol). Molar calculations should use the form on the certificate of analysis.
Naming. Semax is distinct from N-acetyl Semax amidate, a modified analogue with capped ends, and from Selank, which shares only the Pro-Gly-Pro tail.
What is not established about Semax
Its receptor. The receptor or binding site that starts Semax's effects has not been identified.
Functional recovery in occlusion models. The artery occlusion studies report gene and protein changes, not long-term survival or neurological scores [5,6,7].
Independent replication. Most published Semax work comes from a small group of Russian laboratories, and much of the older literature is in Russian.
Pharmacokinetics. No half-life has been established, and the FDA identified no clinical pharmacokinetic studies [8].
Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.